Page last updated: 2024-11-10

sr140333b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SR140333B: a neurokinin-1 receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3047794
CHEMBL ID2105831
MeSH IDM0517791

Synonyms (19)

Synonym
nolpitantium besilate
sr140333b
nolpitantium benzenesulfonate
CHEMBL2105831
nolpitantium besylate
sr 140333b
1-(2-((s)-3-(3,4-dichlorophenyl)-1-((m-isopropoxyphenyl)acetyl)-3-piperidyl)ethyl-4-phenylquinuclidinium benzenesulfonate
unii-sn2g80pk4i
155418-06-7
nolpitantium besilate [inn]
1-(2-((s)-3-(3,4-dichlorophenyl)-1-((m-isopropoxyphenyl)acetyl)-3-piperidyl)ethyl)-4-phenylquinuclidinium benzenesulfonate
sn2g80pk4i ,
1-(2-((s)-3-(3,4-dichlorophenyl)-1-((m-isopropoxyphenyl)acetyl)-3-piperidyl)ethyl-4-phenylquinuclidinium benzenesulphonate
1-azoniabicyclo(2.2.2)octane, 1-(2-((3s)-3-(3,4-dichlorophenyl)-1-((3-(1-methylethoxy)phenyl)acetyl)-3-piperidinyl)ethyl)-4-phenyl-, benzenesulfonate
1-azoniabicyclo(2.2.2)octane, 1-(2-((3s)-3-(3,4-dichlorophenyl)-1-(2-(3-(1-methylethoxy)phenyl)acetyl)-3-piperidinyl)ethyl)-4-phenyl-, benzenesulfonate (1:1)
1-(2-(3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl)ethyl)-4-phenyl-1-azoniabicyclo(2.2.2)octane benzenesulfonate
DTXSID70165897
benzenesulfonate;1-[(3s)-3-(3,4-dichlorophenyl)-3-[2-(4-phenyl-1-azoniabicyclo[2.2.2]octan-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone
Q27289293
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (21.43)29.6817
2010's11 (78.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]